Dermata Therapeutics Inc. Common Stock (DRMA)

FairStock Score: 64/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for durable businesses that earn cash and possess a margin of safety. Dermata, at $0.86 on 2026-10-13, fails the first test. In the filed figures, no revenue is reported. Net losses were $7.8M in fiscal 2023, $12.3M in fiscal 2024, and $7.6M in fiscal 2025. In fiscal Q1 2026, the quarter ended 2026-03-31, the net loss was $1.8M; in fiscal Q2 2026, the quarter ended 2026-06-30, it widened to $3.0M. That is not a business compounding; it is a consumer-skincare venture consuming capital. Trailing free cash flow is negative $8.1M, and the FairStock FCF yield is -235.5% against a $3.5M market cap. The FairStock Piotroski score is 1/9 and FairStock Altman Z-score is -18.65, signs of acute financial fragility. The FairStock P/B of 0.99 at the 2026-10-13 close makes the price look near book value, but book value can evaporate through continued losses. FairStock P/E is -0.20 at the 2026-10-13 close, and reported diluted EPS was -$0.74 in fiscal Q2 2026, the quarter ended 2026-06-30. FairStock ROE is -183.89% and ROCE is -89.88%. There is no Lynch category because the company has lost money in each of the last four years. A competitive moat in dermatology skincare would require brands, repeat purchase, or regulatory protection; the filed figures show no revenue to prove any. The company may be developing Tome products with only nine employees, but hope is not intrinsic value. Growth trajectory remains unproven. Until revenue appears and cash burn shrinks, this is speculation, not a Graham bargain.

In plain English: Dermata Therapeutics is a tiny healthcare company that makes skin-care products under the Tome brand and has only 9 employees. The business looks weak: it reports no revenue and has lost money each year. At $0.86 a share, the price may look low, but because it keeps losing money and burning cash, it does not look clearly cheap.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer